FAK-IN-5

Cat. No.:	HY-147520
CAS No.:	2408317-70-2
Molecular Formula:	$C_{29}H_{29}ClF_3N_3O_4$
Molecular Weight:	576.01
Target:	FAK; Apoptosis; Autophagy
Pathway:	Protein Tyrosine Kinase/RTK; Apoptosis; Autophagy
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	FAK-IN-5 (Compound 8l) is a FAK signaling inhibitor. FAK-IN-5 induces cell apoptosis and autophagy[1].

In Vitro

FAK-IN-5 (Compound 8l) (0-50 μM, 72 h) shows antiproliferative activity against cancer cells[1].
FAK-IN-5 (Compound 8l) causes cell detachment[1].
FAK-IN-5 (Compound 8l) (0-25 μM, 24 h) induces autophagy and apoptosis in HCT-116 cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay[1]

Cell Line:	K562, CEM, G361, MCF-7 and HCT-116
Concentration:	0-50 μM
Incubation Time:	72 h
Result:	Showed antiproliferative activity with IC_{50} values of 6.3, 7.9, 6.3, 5.5 and 5.3 μM against K562, CEM, G361, MCF-7 and HCT-116 cells, respectively.

Western Blot Analysis[1]

Cell Line:	HCT-116
Concentration:	1.25, 2.5, 5, 7, 10, 11, 17 and 25 μM
Incubation Time:	1, 3, 5, 7 and 24 h
Result:	Caused the dephosphorylation of FAK, p130Cas and paxillin in a dose-dependent manner. The dephosphorylation of FAK at Y397 was observed at a much earlier time point. Detected the fragments of activated caspase-7 as well as the dose-dependent cleavage of poly (ADP-ribose) polymerase (PARP).

REFERENCES

[1]. Jorda R, et al. Novel modified leucine and phenylalanine dipeptides modulate viability and attachment of cancer cells. Eur J Med Chem. 2020 Feb 15;188:112036.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA